Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non Operating Income: 2021-2024

Historic Other Non Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Dec 2024 value amounting to $8.9 million.

  • Rhythm Pharmaceuticals' Other Non Operating Income fell 74.82% to $274,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 79.28%. This contributed to the annual value of $8.9 million for FY2024, which is 4584.21% up from last year.
  • According to the latest figures from FY2024, Rhythm Pharmaceuticals' Other Non Operating Income is $8.9 million, which was up 4,584.21% from $190,000 recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Other Non Operating Income registered a high of $100.0 million during FY2021, and its lowest value of -$790,000 during FY2022.
  • For the 3-year period, Rhythm Pharmaceuticals' Other Non Operating Income averaged around $2.8 million, with its median value being $190,000 (2023).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 100.79% in 2022, then soared by 4,584.21% in 2024.
  • Yearly analysis of 4 years shows Rhythm Pharmaceuticals' Other Non Operating Income stood at $100.0 million in 2021, then tumbled by 100.79% to -$790,000 in 2022, then soared by 124.05% to $190,000 in 2023, then surged by 4,584.21% to $8.9 million in 2024.